Filing Flows › AstraZeneca (AZN) › Q3 2025
AstraZeneca (AZN) Q3 2025 earnings results (third quarter 2025)
6-K filed Nov 6, 2025
AstraZeneca (AZN) reported revenue of $15.2B for the third quarter 2025 (Q3 2025), +12% from a year earlier and +5% from the quarter before. Operating margin was 23.6%, net earnings $2.5B (16.7% of revenue).
AstraZeneca, Q3 2025: revenue $15.2B (+12% year over year), operating margin 23.6%, net earnings $2.5B, operating cash flow $6.2B. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $15.2B | +5% | +12% |
| Gross profit | $12.4B | +3% | +18% |
| Operating profit | $3.6B | +2% | +70% |
| Net earnings | $2.5B | +4% | +77% |
| Operating cash flow | $6.2B | — | — |
| Free cash flow | $5.5B | — | — |
What changed
Revenue was $15.2B in Q3 2025, up 12% year over year and up 5% from the previous quarter. Oncology was the largest line at 40% of revenue.
Gross margin was 81.6%, up 4.3 points from a year earlier. Operating profit was $3.6B, a 23.6% margin (up 8.1 points year over year). Of the extra revenue versus a year earlier, 91% reached operating profit, above the 16% margin then. Operating expenses grew 5% against revenue growth of 12%. The fastest-growing cost line was Research & development (+18%). Net earnings were $2.5B, up 77% year over year. The effective tax rate was 21.9%.
Operating cash flow was $6.2B, 246% of net earnings. Working capital and other items added $3.7B. Capital expenditures of $0.69B left free cash flow of $5.5B.
Questions
What was AstraZeneca's revenue in the third quarter 2025?
AstraZeneca (AZN) reported revenue of $15.2B for the third quarter 2025 (Q3 2025), +12% from a year earlier and +5% from the quarter before.
Was AstraZeneca profitable in the third quarter 2025?
Operating profit was $3.6B (23.6% of revenue) and net earnings $2.5B.
Source: AstraZeneca 6-K on SEC EDGAR.